![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SPINT1 |
Gene summary for SPINT1 |
![]() |
Gene information | Species | Human | Gene symbol | SPINT1 | Gene ID | 6692 |
Gene name | serine peptidase inhibitor, Kunitz type 1 | |
Gene Alias | HAI | |
Cytomap | 15q15.1 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | O43278 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6692 | SPINT1 | CA_HPV_1 | Human | Cervix | CC | 1.02e-04 | -2.44e-01 | 0.0264 |
6692 | SPINT1 | Tumor | Human | Cervix | CC | 2.16e-15 | 4.79e-01 | 0.1241 |
6692 | SPINT1 | sample3 | Human | Cervix | CC | 9.66e-25 | 5.62e-01 | 0.1387 |
6692 | SPINT1 | H2 | Human | Cervix | HSIL_HPV | 5.32e-16 | 5.76e-01 | 0.0632 |
6692 | SPINT1 | T3 | Human | Cervix | CC | 5.30e-22 | 5.53e-01 | 0.1389 |
6692 | SPINT1 | HTA11_3410_2000001011 | Human | Colorectum | AD | 4.60e-04 | 3.19e-01 | 0.0155 |
6692 | SPINT1 | HTA11_2487_2000001011 | Human | Colorectum | SER | 6.83e-23 | 1.15e+00 | -0.1808 |
6692 | SPINT1 | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.73e-11 | 6.90e-01 | -0.0811 |
6692 | SPINT1 | HTA11_78_2000001011 | Human | Colorectum | AD | 3.54e-09 | 6.01e-01 | -0.1088 |
6692 | SPINT1 | HTA11_347_2000001011 | Human | Colorectum | AD | 4.26e-35 | 1.07e+00 | -0.1954 |
6692 | SPINT1 | HTA11_411_2000001011 | Human | Colorectum | SER | 5.45e-11 | 1.92e+00 | -0.2602 |
6692 | SPINT1 | HTA11_2112_2000001011 | Human | Colorectum | SER | 3.89e-05 | 1.02e+00 | -0.2196 |
6692 | SPINT1 | HTA11_3361_2000001011 | Human | Colorectum | AD | 1.55e-09 | 7.84e-01 | -0.1207 |
6692 | SPINT1 | HTA11_83_2000001011 | Human | Colorectum | SER | 9.97e-11 | 6.83e-01 | -0.1526 |
6692 | SPINT1 | HTA11_696_2000001011 | Human | Colorectum | AD | 6.78e-26 | 7.96e-01 | -0.1464 |
6692 | SPINT1 | HTA11_866_2000001011 | Human | Colorectum | AD | 2.63e-15 | 5.71e-01 | -0.1001 |
6692 | SPINT1 | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.24e-17 | 8.62e-01 | -0.059 |
6692 | SPINT1 | HTA11_5212_2000001011 | Human | Colorectum | AD | 3.70e-13 | 1.09e+00 | -0.2061 |
6692 | SPINT1 | HTA11_5216_2000001011 | Human | Colorectum | SER | 9.98e-05 | 7.89e-01 | -0.1462 |
6692 | SPINT1 | HTA11_546_2000001011 | Human | Colorectum | AD | 1.05e-08 | 7.17e-01 | -0.0842 |
Page: 1 2 3 4 5 6 7 8 9 10 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00018415 | Liver | HCC | neural tube formation | 62/7958 | 102/18723 | 1.47e-04 | 1.18e-03 | 62 |
GO:005134622 | Liver | HCC | negative regulation of hydrolase activity | 195/7958 | 379/18723 | 2.44e-04 | 1.82e-03 | 195 |
GO:001072011 | Liver | HCC | positive regulation of cell development | 155/7958 | 298/18723 | 5.39e-04 | 3.48e-03 | 155 |
GO:000189211 | Liver | HCC | embryonic placenta development | 50/7958 | 82/18723 | 5.62e-04 | 3.61e-03 | 50 |
GO:000189011 | Liver | HCC | placenta development | 81/7958 | 144/18723 | 5.91e-04 | 3.75e-03 | 81 |
GO:00018433 | Liver | HCC | neural tube closure | 53/7958 | 88/18723 | 5.95e-04 | 3.75e-03 | 53 |
GO:00140204 | Liver | HCC | primary neural tube formation | 56/7958 | 94/18723 | 6.19e-04 | 3.86e-03 | 56 |
GO:00606063 | Liver | HCC | tube closure | 53/7958 | 89/18723 | 8.67e-04 | 5.14e-03 | 53 |
GO:00606694 | Liver | HCC | embryonic placenta morphogenesis | 19/7958 | 26/18723 | 1.57e-03 | 8.23e-03 | 19 |
GO:00219154 | Liver | HCC | neural tube development | 82/7958 | 152/18723 | 2.83e-03 | 1.33e-02 | 82 |
GO:00507674 | Liver | HCC | regulation of neurogenesis | 181/7958 | 364/18723 | 3.00e-03 | 1.40e-02 | 181 |
GO:001095121 | Liver | HCC | negative regulation of endopeptidase activity | 129/7958 | 252/18723 | 3.17e-03 | 1.47e-02 | 129 |
GO:00507693 | Liver | HCC | positive regulation of neurogenesis | 116/7958 | 225/18723 | 3.67e-03 | 1.63e-02 | 116 |
GO:00018384 | Liver | HCC | embryonic epithelial tube formation | 66/7958 | 121/18723 | 4.94e-03 | 2.07e-02 | 66 |
GO:001046621 | Liver | HCC | negative regulation of peptidase activity | 132/7958 | 262/18723 | 5.82e-03 | 2.42e-02 | 132 |
GO:0060674 | Liver | HCC | placenta blood vessel development | 20/7958 | 30/18723 | 6.52e-03 | 2.65e-02 | 20 |
GO:00607114 | Liver | HCC | labyrinthine layer development | 27/7958 | 44/18723 | 8.98e-03 | 3.46e-02 | 27 |
GO:00721754 | Liver | HCC | epithelial tube formation | 70/7958 | 132/18723 | 9.29e-03 | 3.57e-02 | 70 |
GO:00420631 | Liver | HCC | gliogenesis | 148/7958 | 301/18723 | 1.10e-02 | 4.07e-02 | 148 |
GO:006145811 | Liver | HCC | reproductive system development | 205/7958 | 427/18723 | 1.16e-02 | 4.27e-02 | 205 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa052157 | Cervix | CC | Prostate cancer | 27/1267 | 97/8465 | 7.54e-04 | 3.39e-03 | 2.01e-03 | 27 |
hsa0521512 | Cervix | CC | Prostate cancer | 27/1267 | 97/8465 | 7.54e-04 | 3.39e-03 | 2.01e-03 | 27 |
hsa05215 | Colorectum | AD | Prostate cancer | 35/2092 | 97/8465 | 7.95e-03 | 3.13e-02 | 2.00e-02 | 35 |
hsa052151 | Colorectum | AD | Prostate cancer | 35/2092 | 97/8465 | 7.95e-03 | 3.13e-02 | 2.00e-02 | 35 |
hsa052152 | Colorectum | FAP | Prostate cancer | 28/1404 | 97/8465 | 1.67e-03 | 8.57e-03 | 5.21e-03 | 28 |
hsa05202 | Colorectum | FAP | Transcriptional misregulation in cancer | 45/1404 | 193/8465 | 9.19e-03 | 3.33e-02 | 2.03e-02 | 45 |
hsa052153 | Colorectum | FAP | Prostate cancer | 28/1404 | 97/8465 | 1.67e-03 | 8.57e-03 | 5.21e-03 | 28 |
hsa052021 | Colorectum | FAP | Transcriptional misregulation in cancer | 45/1404 | 193/8465 | 9.19e-03 | 3.33e-02 | 2.03e-02 | 45 |
hsa0521516 | Esophagus | ESCC | Prostate cancer | 72/4205 | 97/8465 | 6.12e-07 | 4.10e-06 | 2.10e-06 | 72 |
hsa052028 | Esophagus | ESCC | Transcriptional misregulation in cancer | 116/4205 | 193/8465 | 2.08e-03 | 5.95e-03 | 3.05e-03 | 116 |
hsa0521517 | Esophagus | ESCC | Prostate cancer | 72/4205 | 97/8465 | 6.12e-07 | 4.10e-06 | 2.10e-06 | 72 |
hsa0520213 | Esophagus | ESCC | Transcriptional misregulation in cancer | 116/4205 | 193/8465 | 2.08e-03 | 5.95e-03 | 3.05e-03 | 116 |
hsa0521510 | Oral cavity | OSCC | Prostate cancer | 66/3704 | 97/8465 | 1.05e-06 | 5.89e-06 | 3.00e-06 | 66 |
hsa0521515 | Oral cavity | OSCC | Prostate cancer | 66/3704 | 97/8465 | 1.05e-06 | 5.89e-06 | 3.00e-06 | 66 |
hsa0521524 | Oral cavity | EOLP | Prostate cancer | 31/1218 | 97/8465 | 7.90e-06 | 4.73e-05 | 2.79e-05 | 31 |
hsa0521534 | Oral cavity | EOLP | Prostate cancer | 31/1218 | 97/8465 | 7.90e-06 | 4.73e-05 | 2.79e-05 | 31 |
hsa0521542 | Oral cavity | NEOLP | Prostate cancer | 28/1112 | 97/8465 | 3.15e-05 | 2.57e-04 | 1.62e-04 | 28 |
hsa0521552 | Oral cavity | NEOLP | Prostate cancer | 28/1112 | 97/8465 | 3.15e-05 | 2.57e-04 | 1.62e-04 | 28 |
hsa052159 | Prostate | BPH | Prostate cancer | 48/1718 | 97/8465 | 1.08e-10 | 1.87e-09 | 1.16e-09 | 48 |
hsa052027 | Prostate | BPH | Transcriptional misregulation in cancer | 53/1718 | 193/8465 | 9.56e-03 | 2.92e-02 | 1.81e-02 | 53 |
Page: 1 2 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SPINT1 | SNV | Missense_Mutation | novel | c.529G>A | p.Glu177Lys | p.E177K | O43278 | protein_coding | deleterious(0.03) | benign(0.038) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SPINT1 | SNV | Missense_Mutation | c.562N>T | p.Asp188Tyr | p.D188Y | O43278 | protein_coding | deleterious(0.02) | probably_damaging(0.915) | TCGA-E2-A1LA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD | |
SPINT1 | insertion | Nonsense_Mutation | novel | c.1318_1319insAGTTTA | p.Ser440delinsTer | p.S440delins* | O43278 | protein_coding | TCGA-AN-A03X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
SPINT1 | insertion | Frame_Shift_Ins | novel | c.1321_1322insTTGTGCCTACAGTTATT | p.Cys441PhefsTer18 | p.C441Ffs*18 | O43278 | protein_coding | TCGA-AN-A03X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
SPINT1 | deletion | Frame_Shift_Del | novel | c.1547delN | p.Asp516AlafsTer155 | p.D516Afs*155 | O43278 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
SPINT1 | SNV | Missense_Mutation | c.1552N>A | p.Glu518Lys | p.E518K | O43278 | protein_coding | deleterious(0.04) | probably_damaging(0.994) | TCGA-UC-A7PF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
SPINT1 | SNV | Missense_Mutation | novel | c.1004N>A | p.Cys335Tyr | p.C335Y | O43278 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-VS-A8EL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SPINT1 | SNV | Missense_Mutation | rs751324782 | c.1103N>T | p.Ala368Val | p.A368V | O43278 | protein_coding | tolerated(0.43) | benign(0.031) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
SPINT1 | SNV | Missense_Mutation | c.1525T>A | p.Ser509Thr | p.S509T | O43278 | protein_coding | tolerated(0.19) | possibly_damaging(0.452) | TCGA-AZ-6598-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
SPINT1 | SNV | Missense_Mutation | c.1310G>A | p.Cys437Tyr | p.C437Y | O43278 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
6692 | SPINT1 | PROTEASE INHIBITOR, DRUGGABLE GENOME | SURAMIN | SURAMIN | 15590895 |
Page: 1 |